pyrroles has been researched along with Cerebral Infarction in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (66.67) | 29.6817 |
| 2010's | 6 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, S; Kim, E; Park, KW; Yang, J | 1 |
| Hattori, N; Oji, Y; Sekiguchi, K; Tanaka, R; Tanaka, Y; Tomizawa, Y; Yamashiro, K | 1 |
| Luo, YH; Wang, YY; Xie, YM; Yang, W; You, L; Zhuang, Y | 1 |
| Zuber, M | 1 |
| Hasegawa, Y; Isahaya, K; Kato, B; Sakurai, K; Shimizu, K; Shimomura, K; Takaishi, S; Tokuyama, Y | 1 |
| Beer, C; Blacker, D; Bynevelt, M; Hankey, GJ; Puddey, IB | 1 |
| Daida, H; Hasegawa, Y; Hirayama, A; Hiro, T; Kadota, K; Kimura, K; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ozaki, Y; Uchiyama, S; Yamagishi, M | 1 |
| Fushimi, H | 1 |
| Hu, ZP; Jiang, B; Nie, S; Tan, LM; Wu, J; Xiao, ZJ; Zhao, SP; Zhou, HN | 1 |
| Chen, AF; Hong, H; Kaufman, DI; Kreulen, DL; Zeng, JS | 1 |
| Amarenco, P; Bogousslavsky, J; Callahan, A; Goldstein, LB; Hennerici, M; Rudolph, AE; Sillesen, H; Simunovic, L; Szarek, M; Welch, KM; Zivin, JA | 1 |
| Pogacnik, T; Pretnar-Oblak, J; Sabovic, M; Sebestjen, M; Zaletel, M | 1 |
| Håberg, A; Hjelstuen, MH; Qu, H; Sonnewald, U | 1 |
| Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, M; Sillesen, H; Szarek, M; Welch, KM; Zivin, JA | 1 |
| Karam, JG; Loney-Hutchinson, L; McFarlane, SI | 1 |
| Callahan, A | 1 |
2 review(s) available for pyrroles and Cerebral Infarction
| Article | Year |
|---|---|
[Treatment of cerebral infarction patients with IGT].
Topics: Antidepressive Agents; Antipyrine; Atorvastatin; Cerebral Infarction; Edaravone; Free Radical Scavengers; Glucose Intolerance; Heptanoic Acids; Humans; Hyperglycemia; Hypertension; Hypertriglyceridemia; Insulin Resistance; Pyrroles; Secondary Prevention; Thrombolytic Therapy | 2005 |
Cerebrovascular disease and statins: a potential addition to the therapeutic armamentarium for stroke prevention.
Topics: Anticholesteremic Agents; Atorvastatin; Cerebral Infarction; Cholesterol; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Intracranial Arteriosclerosis; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic | 2001 |
4 trial(s) available for pyrroles and Cerebral Infarction
| Article | Year |
|---|---|
A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Biphenyl Compounds; Brain Ischemia; Cerebral Infarction; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Irbesartan; Male; Middle Aged; Monitoring, Physiologic; Pyrroles; Sample Size; Stroke; Tetrazoles; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
[Effects of atorvastatin on plasma hypersensitive C-reactive protein and interleukin-6 in patients with acute cerebral infarction].
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; C-Reactive Protein; Cerebral Infarction; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Male; Middle Aged; Pyrroles | 2005 |
High-dose atorvastatin after stroke or transient ischemic attack.
Topics: Adult; Atorvastatin; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Proportional Hazards Models; Pyrroles; Risk; Secondary Prevention; Stroke | 2006 |
Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cerebral Infarction; Cholesterol, LDL; Comorbidity; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Pyrroles; Risk Assessment; Secondary Prevention; Sex Factors | 2008 |
12 other study(ies) available for pyrroles and Cerebral Infarction
| Article | Year |
|---|---|
Inhibition of VEGF Signaling Reduces Diabetes-Exacerbated Brain Swelling, but Not Infarct Size, in Large Cerebral Infarction in Mice.
Topics: Animals; Blood Glucose; Brain Edema; Brain Ischemia; Cerebral Infarction; Diabetes Mellitus, Experimental; Disease Models, Animal; Glucose Tolerance Test; Indoles; Insulin; Male; Mice; Mice, Inbred C57BL; Protein Kinase Inhibitors; Proteoglycans; Pyrroles; RNA, Messenger; Signal Transduction; Stroke; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
Cerebral infarction in a case of Parry-Romberg syndrome.
Topics: Adult; Aspirin; Atorvastatin; Cerebral Infarction; Diffusion Magnetic Resonance Imaging; Facial Hemiatrophy; Female; Fibrinolytic Agents; Foramen Ovale, Patent; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors; Treatment Outcome | 2014 |
[Analysis of clinical use of shuxuening injection in treatment of cerebral infarction based on real world].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atorvastatin; Cerebral Infarction; Drugs, Chinese Herbal; Female; Heptanoic Acids; Humans; Male; Middle Aged; Piperazines; Pyrroles; Young Adult | 2014 |
[Vascular prevention after cerebral infarct or transient ischemic accident. Recommendations. March, 2008].
Topics: Anticholesteremic Agents; Atorvastatin; Brain; Cerebral Infarction; Cerebrovascular Circulation; Coronary Disease; Heptanoic Acids; Humans; Hypertension; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Pyrroles; Risk Factors; Time Factors | 2008 |
[High dosage stain protects heart and brain from recurrence].
Topics: Anticholesteremic Agents; Atorvastatin; Cerebral Infarction; Cholesterol, LDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention | 2008 |
[Effects of early statin treatment on inflammatory biomarkers and clinical deterioration in patients with acute ischemic stroke].
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Cerebral Infarction; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukins; Male; Matrix Metalloproteinases; Prospective Studies; Pyrroles; Time Factors | 2011 |
Reverse vessel remodeling but not coronary plaque regression could predict future cardiovascular events in ACS patients with intensive statin therapy--the extended JAPAN-ACS study.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; Biomarkers; Cerebral Infarction; Cholesterol, HDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Plaque, Atherosclerotic; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Quinolines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2012 |
[Following the ASCOT Study. A statin for every hypertensive patient?].
Topics: Anticholesteremic Agents; Atorvastatin; Cerebral Infarction; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Treatment Outcome | 2003 |
Atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in ischemic stroke.
Topics: Animals; Atorvastatin; Cerebral Infarction; Disease Models, Animal; Heptanoic Acids; Male; NADPH Oxidases; Neuroprotective Agents; Nitric Oxide Synthase Type II; Pyrroles; Rats; Rats, Sprague-Dawley; Superoxides; Time Factors | 2006 |
Influence of atorvastatin treatment on L-arginine cerebrovascular reactivity and flow-mediated dilatation in patients with lacunar infarctions.
Topics: Aged; Anticholesteremic Agents; Arginine; Atorvastatin; Blood Pressure; Carbon Dioxide; Cerebral Infarction; Cerebrovascular Circulation; Comorbidity; Endothelium, Vascular; Female; Follow-Up Studies; Heart Rate; Hemorheology; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Single-Blind Method; Ultrasonography, Doppler, Transcranial; Vasodilation; Vasodilator Agents | 2006 |
Effect of the pyrrolopyrimidine lipid peroxidation inhibitor U-101033E on neuronal and astrocytic metabolism and infarct volume in rats with transient middle cerebral artery occlusion.
Topics: Acetates; Animals; Astrocytes; Cerebral Infarction; Disease Models, Animal; Glucose; Glycolysis; Lipid Peroxidation; Magnetic Resonance Imaging; Male; Middle Cerebral Artery; Nerve Tissue Proteins; Neurons; Pyrimidines; Pyrroles; Pyrrolidines; Rats; Rats, Wistar | 2007 |
High-dose atorvastatin after stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.
Topics: Adult; Atorvastatin; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk; Stroke | 2008 |